Mid- to longterm outcome after severe COVID-19 associated respiratory failure with Extracorporeal Membrane Oxygenation (ECMO) therapy
- Conditions
- COVID-19-related severe hypoxemic respiratory failure
- Registration Number
- DRKS00026752
- Lead Sponsor
- Herz- u. Diabeteszentrum NRW, Klinik für Thorax- und Kardiovaskularchirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Covid-19 patients treated with ECMO therapy at the HDZ NRW since the beginning of the pandemic until April 2021.
Exclusion Criteria
none
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Health status and quality of life one year, two years, and five years after initiation of ECMO therapy. The surveys are conducted using standardized and established questionnaires in telephone or postal form.
- Secondary Outcome Measures
Name Time Method